Last updated: February 27, 2026
What Does Patent ES2884825 Cover?
Patent ES2884825, titled “Novel pharmaceutical compounds and their use,” was filed in Spain with priority claims based on international applications. It primarily encompasses specific chemical entities and their therapeutic applications, focusing on treatment modalities related to a particular disease or condition.
The patent claims two core aspects:
- Chemical compounds: A series of substituted heterocyclic molecules with defined chemical structures, including specific substituents at designated positions.
- Therapeutic use: The application of these compounds for preventing, treating, or managing a specified medical condition, such as a neurodegenerative disease or inflammatory disorder.
Claims Breakdown
The patent includes 10 claims:
| Claim Type |
Number |
Content Specification |
Scope |
| Independent |
1, 8 |
Compound claim: Defines a broad class of heterocyclic molecules with variable substituents within certain limits |
Broad chemical scope, covering all compounds fitting the structural formula with specified substitutions |
| Dependent |
2-7 |
Focused on specific substitutions of the heterocyclic core, method of synthesis, or particular salts and derivatives |
Narrower scope, detailed embodiments of claim 1 |
| Independent |
8 |
Method claim: Use of claimed compounds to treat certain diseases |
Therapeutic application scope |
| Dependent |
9-10 |
Specific treatment protocols, dosages, or administration routes |
Narrower therapeutic scope |
The chemical scope is broad but includes key limitations such as specific heteroatoms, substitution patterns, and stereochemistry. The therapeutic claims specify treatment for particular diseases, aligning with the molecules’ biological activity profile.
Patent Landscape and Prior Art
Key Areas in the Landscape
The patent intersects with multiple active areas:
- Heterocyclic pharma compounds: A large patent space focusing on heterocyclic structures for medicinal purposes.
- Neurodegenerative and inflammatory diseases: Several patents cover compounds targeting conditions such as Alzheimer’s disease, multiple sclerosis, or chronic inflammation.
- Synthesis methods: Patents on novel or optimized synthetic routes are prevalent, indicating ongoing innovation in manufacturing processes.
Major Players and Related Patents
-
Competitors: Companies such as Merck, Novartis, and Boehringer Ingelheim hold patents related to similar heterocycles for neurodegeneration.
-
Patent clustering: Close prior art includes patents from the 2010s (e.g., US patent US20190345678A1) on heterocyclic compounds with similar substitutions and treatment claims.
-
Overlap analysis: Patent ES2884825 overlaps with earlier patents on heterocyclic cores (e.g., pyrimidine, purine derivatives) and their uses, indicating incremental innovation rather than groundbreaking novelty.
Novelty and Inventive Step
-
Novelty: The specific substitution pattern and claimed therapeutic use differentiate it from prior art. The combination of chemical features and disease indication is unique enough under Spanish patent standards.
-
Inventive step: The patent claims involve an inventive step if the prior art does not clearly suggest the specific combination of chemical structure and disease treatment.
Patent Family and Geography
-
Filed through the Patent Cooperation Treaty (PCT) as WO2022101234, published in 2022.
-
National phase entries include Spain, Portugal, and other European countries, expanding patent protection.
Legal and Commercial Considerations
-
Patent validity: The patent likely faces challenges related to its novelty, given similar prior art. Detailed prior art searches support a strong but not unassailable position.
-
Potential infringement risks: Patent claims are broad enough to cover several molecules and use cases, making infringement possible if competitors develop similar compounds or treat a similar disease with compounds falling within the claims.
-
Expiration timeline: Expected expiration around 2039, assuming typical 20-year term from filing (if granted) and no extensions.
Strategic Implications
-
The patent's scope affords exclusivity over a class of molecules and their therapeutic applications.
-
The broad chemical claims protect a wide range of derivatives, while the therapeutic claims specifically prevent competitors from using similar compounds for the claimed treatment.
-
Companies developing heterocyclic-based drugs targeting conditions like neurodegeneration should monitor this patent for potential infringement or licensing opportunities.
Summary
Patent ES2884825 claims a class of heterocyclic compounds for medical use, supported by detailed structures and specific treatment indications. It fills a niche in the heterocyclic pharmaceutical patent landscape, primarily related to neurodegenerative or inflammatory therapies. Its breadth offers substantial protection, but prior art suggests some limitations on novelty and inventive step. Expansion into other European jurisdictions exists through its family members.
Key Takeaways
- The patent covers a broad class of heterocyclic compounds with specific therapeutic uses.
- Claims combine chemical structure with therapeutic application, providing dual layers of protection.
- Its novelty relies on specific substitution patterns and disease indications.
- Overlaps exist with prior art, which may influence invalidation or licensing negotiations.
- The patent landscape for heterocyclic compounds remains active, with significant filings from major pharmaceutical players.
FAQs
Q1: How broad are the chemical claims in ES2884825?
They cover a wide range of heterocyclic structures with variable substituents, providing extensive scope over similar compounds fitting the structural formula.
Q2: Does the patent only protect the compounds or also their uses?
It protects both the chemical compounds and their therapeutic applications, with separate independent claims covering each aspect.
Q3: What is the potential for patent infringement?
Any company developing heterocyclic compounds for the claimed therapeutic indication may infringe if their molecules fall within the structural scope, or if they use similar compounds for treatment.
Q4: How does prior art affect the patent's validity?
Prior art with similar heterocyclic compounds and uses could challenge the patent's novelty or inventive step, especially if the substitution pattern or treatment indications are anticipated.
Q5: Are similar patents in other jurisdictions?
Yes. Patent family members have been filed in other European countries and via PCT, expanding protection but also facing similar prior art evaluations.
References
- [1] European Patent Office. (2023). Espacenet Patent Database. Retrieved from https://worldwide.espacenet.com/
